Innoviva, Inc. (INVA)
NASDAQ: INVA · Real-Time Price · USD
20.83
+0.19 (0.92%)
Oct 6, 2026, 4:00 PM EDT - Market closed
Innoviva Employees
Innoviva had 159 employees as of December 31, 2025. The number of employees increased by 32 or 25.20% compared to the previous year.
Employees
159
Change (1Y)
32
Growth (1Y)
25.20%
Revenue / Employee
$2,767,283
Profits / Employee
$2,246,767
Market Cap
1.50B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| Immunocore Holdings | 524 |
| Ocular Therapeutix | 325 |
| Maze Therapeutics | 141 |
| Inhibrx Biosciences | 110 |
| AnaptysBio | 104 |
| Taysha Gene Therapies | 99 |
| Tyra Biosciences | 87 |
INVA News
- 1 day ago - Russian plague outbreak could boost these under-the-radar pharma stocks - Invezz
- 13 days ago - Innoviva assumed with an Outperform at Oppenheimer - TheFly
- 22 days ago - Innoviva Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 26 days ago - Innoviva Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference - Transcripts
- 4 weeks ago - Innoviva to Participate in Upcoming Investor Conferences - Business Wire
- 7 weeks ago - Innoviva management to meet virtually with Cantor Fitzgerald - TheFly
- 1 month ago - Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award - Business Wire
- 2 months ago - Innoviva price target lowered to $34 from $36 at Cantor Fitzgerald - TheFly